For example, germline mutations of the ALK receptor tyrosine kinase (ALK) gene are involved in the etiology of a subset of neuroblastomas (Mosse et al., 2008) and somatic ALK gain-of-function mutations, gene amplifications, and gene fusions are oncogenic drivers and therapeutic targets for neuroblastoma and anaplastic large cell lymphoma (Mosse et al., 2017). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.